Société Tunisienne des Maladies Respiratoires et d'Allergologie STMRA - Study shows reduced neutralizing antibody activity induced by Pfizer–BioNTech vaccine against SARS-CoV-2 variants of concern B.1.617.2 (Delta) and B.1.351 (Beta).

Sté Tunisienne des Maladies Respiratoires et d'Allergologie

Cercle des Bureaux - Appartement B 5-3 . 1082 Centre urbain Nord Tunis

Study shows reduced neutralizing antibody activity induced by Pfizer–BioNTech vaccine against SARS-CoV-2 variants of concern B.1.617.2 (Delta) and B.1.351 (Beta).

Zouhair Souissi

Bibliographie

7 juin 2021

Soyez le premier à commenter!

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 (Beta) by BNT162b2 vaccination – The Lancet Commentary: Pfizer-BioNTech vaccine recipients have lower antibody levels targeting the Delta variant – The Francis Crick Institute Commentary on Twitter (thread – click for more) “Immune escape” in #DeltaVariant. That’s the latest finding – that #B16172 is as […]

The post Study shows reduced neutralizing antibody activity induced by Pfizer–BioNTech vaccine against SARS-CoV-2 variants of concern B.1.617.2 (Delta) and B.1.351 (Beta). appeared first on Links Medicus.

Lu 574 fois